{
  "functional_evidence_assessment": [
    {
      "variant_id": {
        "Gene": "SNCA",
        "Protein_Change": {
          "ref": "A",
          "alt": "T",
          "position": "53"
        },
        "variant_string_id": "SNCA A53T"
      },
      "functional_evidence_aim": "Pathogenic",
      "assessment_steps": [
        {
          "step_name": "Step 1: Define the disease mechanism",
          "extracted_paper_info": "Strong genetic and experimental data have linked several autosomal dominant parkinsonian syndromes to three human mutations in the gene encoding for a-synuclein (Polymeropoulos et al. 1997): A53T and A30P point mutations in a German kindred, and an E46K mutation in a Spanish family (Kruger et al. 1998). Each of these mutations promotes a-synuclein aggregation in vitro bolstering the view that, in PD, a-synuclein aggregation is a major event in the development of Lewy body pathology.",
          "judgment": "Yes",
          "reasoning": "The paper explicitly defines the disease mechanism as a-synuclein aggregation in PD, directly linking the mutations to pathogenicity."
        },
        {
          "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
          "extracted_paper_info": "In vitro studies have shown that recombinant a-synuclein can aggregate to form amyloid fibrils that resemble Lewy bodies (Narhi et al. 1999), and a-synuclein promotes Lewy body-like inclusion formation in neural tissues (Sampathu et al. 2003; Quilty et al. 2006).",
          "judgment": "Yes",
          "reasoning": "The in vitro aggregation assays directly model the disease mechanism of Lewy body formation, which is central to PD pathogenesis."
        },
        {
          "step_name": "Step 3: Evaluate validity of specific instances of assays",
          "extracted_paper_info": "Each of these mutations promotes a-synuclein aggregation in vitro bolstering the view that, in PD, a-synuclein aggregation is a major event in the development of Lewy body pathology.",
          "judgment": "Yes",
          "reasoning": "The assay (aggregation in vitro) is validated by prior studies (Narhi et al. 1999; Sampathu et al. 2003; Quilty et al. 2006) and directly relates to the defined disease mechanism.",
          "next_step_or_outcome": "Proceed to Step 4"
        },
        {
          "step_name": "Step 4: Apply evidence to individual variant interpretation",
          "extracted_paper_info": "Each of these mutations promotes a-synuclein aggregation in vitro bolstering the view that, in PD, a-synuclein aggregation is a major event in the development of Lewy body pathology.",
          "judgment": "Yes",
          "reasoning": "The variant is associated with familial PD and directly linked to a-synuclein aggregation, which is a core pathogenic mechanism."
        },
        {
          "step_name": "Sub-step 4b: No OddsPath Calculation",
          "extracted_paper_info": "The paper does not report statistical analyses or OddsPath calculations for these variants.",
          "judgment": "No",
          "reasoning": "No OddsPath calculation is provided, so the number of control variants used cannot be quantified.",
          "next_step_or_outcome": "Max PS3_supporting"
        }
      ],
      "strength": "PS3_supporting",
      "overall_conclusion": "The A53T mutation is strongly associated with autosomal dominant Parkinsonian syndromes and directly promotes a-synuclein aggregation, which is a central pathological mechanism in PD. This provides supporting evidence for pathogenicity under PS3."
    },
    {
      "variant_id": {
        "Gene": "SNCA",
        "Protein_Change": {
          "ref": "A",
          "alt": "P",
          "position": "30"
        },
        "variant_string_id": "SNCA A30P"
      },
      "functional_evidence_aim": "Pathogenic",
      "assessment_steps": [
        {
          "step_name": "Step 1: Define the disease mechanism",
          "extracted_paper_info": "Strong genetic and experimental data have linked several autosomal dominant parkinsonian syndromes to three human mutations in the gene encoding for a-synuclein (Polymeropoulos et al. 1997): A53T and A30P point mutations in a German kindred, and an E46K mutation in a Spanish family (Kruger et al. 1998). Each of these mutations promotes a-synuclein aggregation in vitro bolstering the view that, in PD, a-synuclein aggregation is a major event in the development of Lewy body pathology.",
          "judgment": "Yes",
          "reasoning": "The paper explicitly defines the disease mechanism as a-synuclein aggregation in PD, directly linking the mutations to pathogenicity."
        },
        {
          "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
          "extracted_paper_info": "In vitro studies have shown that recombinant a-synuclein can aggregate to form amyloid fibrils that resemble Lewy bodies (Narhi et al. 1999), and a-synuclein promotes Lewy body-like inclusion formation in neural tissues (Sampathu et al. 2003; Quilty et al. 2006).",
          "judgment": "Yes",
          "reasoning": "The in vitro aggregation assays directly model the disease mechanism of Lewy body formation, which is central to PD pathogenesis."
        },
        {
          "step_name": "Step 3: Evaluate validity of specific instances of assays",
          "extracted_paper_info": "Each of these mutations promotes a-synuclein aggregation in vitro bolstering the view that, in PD, a-synuclein aggregation is a major event in the development of Lewy body pathology.",
          "judgment": "Yes",
          "reasoning": "The assay (aggregation in vitro) is validated by prior studies (Narhi et al. 1999; Sampathu et al. 2003; Quilty et al. 2006) and directly relates to the defined disease mechanism.",
          "next_step_or_outcome": "Proceed to Step 4"
        },
        {
          "step_name": "Step 4: Apply evidence to individual variant interpretation",
          "extracted_paper_info": "Each of these mutations promotes a-synuclein aggregation in vitro bolstering the view that, in PD, a-synuclein aggregation is a major event in the development of Lewy body pathology.",
          "judgment": "Yes",
          "reasoning": "The variant is associated with familial PD and directly linked to a-synuclein aggregation, which is a core pathogenic mechanism."
        },
        {
          "step_name": "Sub-step 4b: No OddsPath Calculation",
          "extracted_paper_info": "The paper does not report statistical analyses or OddsPath calculations for these variants.",
          "judgment": "No",
          "reasoning": "No OddsPath calculation is provided, so the number of control variants used cannot be quantified.",
          "next_step_or_outcome": "Max PS3_supporting"
        }
      ],
      "strength": "PS3_supporting",
      "overall_conclusion": "The A30P mutation is strongly associated with autosomal dominant Parkinsonian syndromes and directly promotes a-synuclein aggregation, which is a central pathological mechanism in PD. This provides supporting evidence for pathogenicity under PS3."
    },
    {
      "variant_id": {
        "Gene": "SNCA",
        "Protein_Change": {
          "ref": "E",
          "alt": "K",
          "position": "46"
        },
        "variant_string_id": "SNCA E46K"
      },
      "functional_evidence_aim": "Pathogenic",
      "assessment_steps": [
        {
          "step_name": "Step 1: Define the disease mechanism",
          "extracted_paper_info": "Strong genetic and experimental data have linked several autosomal dominant parkinsonian syndromes to three human mutations in the gene encoding for a-synuclein (Polymeropoulos et al. 1997): A53T and A30P point mutations in a German kindred, and an E46K mutation in a Spanish family (Kruger et al. 1998). Each of these mutations promotes a-synuclein aggregation in vitro bolstering the view that, in PD, a-synuclein aggregation is a major event in the development of Lewy body pathology.",
          "judgment": "Yes",
          "reasoning": "The paper explicitly defines the disease mechanism as a-synuclein aggregation in PD, directly linking the mutations to pathogenicity."
        },
        {
          "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
          "extracted_paper_info": "In vitro studies have shown that recombinant a-synuclein can aggregate to form amyloid fibrils that resemble Lewy bodies (Narhi et al. 1999), and a-synuclein promotes Lewy body-like inclusion formation in neural tissues (Sampathu et al. 2003; Quilty et al. 2006).",
          "judgment": "Yes",
          "reasoning": "The in vitro aggregation assays directly model the disease mechanism of Lewy body formation, which is central to PD pathogenesis."
        },
        {
          "step_name": "Step 3: Evaluate validity of specific instances of assays",
          "extracted_paper_info": "Each of these mutations promotes a-synuclein aggregation in vitro bolstering the view that, in PD, a-synuclein aggregation is a major event in the development of Lewy body pathology.",
          "judgment": "Yes",
          "reasoning": "The assay (aggregation in vitro) is validated by prior studies (Narhi et al. 1999; Sampathu et al. 2003; Quilty et al. 2006) and directly relates to the defined disease mechanism.",
          "next_step_or_outcome": "Proceed to Step 4"
        },
        {
          "step_name": "Step 4: Apply evidence to individual variant interpretation",
          "extracted_paper_info": "Each of these mutations promotes a-synuclein aggregation in vitro bolstering the view that, in PD, a-synuclein aggregation is a major event in the development of Lewy body pathology.",
          "judgment": "Yes",
          "reasoning": "The variant is associated with familial PD and directly linked to a-synuclein aggregation, which is a core pathogenic mechanism."
        },
        {
          "step_name": "Sub-step 4b: No OddsPath Calculation",
          "extracted_paper_info": "The paper does not report statistical analyses or OddsPath calculations for these variants.",
          "judgment": "No",
          "reasoning": "No OddsPath calculation is provided, so the number of control variants used cannot be quantified.",
          "next_step_or_outcome": "Max PS3_supporting"
        }
      ],
      "strength": "PS3_supporting",
      "overall_conclusion": "The E46K mutation is strongly associated with autosomal dominant Parkinsonian syndromes and directly promotes a-synuclein aggregation, which is a central pathological mechanism in PD. This provides supporting evidence for pathogenicity under PS3."
    }
  ]
}